These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 28119489

  • 1. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.
    Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA, Pollock PM.
    Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
    [Abstract] [Full Text] [Related]

  • 2. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ.
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [Abstract] [Full Text] [Related]

  • 3. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [Abstract] [Full Text] [Related]

  • 4. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
    Yu Y, Hall T, Eathiraj S, Wick MJ, Schwartz B, Abbadessa G.
    Anticancer Drugs; 2017 Jun; 28(5):503-513. PubMed ID: 28240679
    [Abstract] [Full Text] [Related]

  • 5. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
    Packer LM, Stehbens SJ, Bonazzi VF, Gunter JH, Ju RJ, Ward M, Gartside MG, Byron SA, Pollock PM.
    Mol Oncol; 2019 Apr; 13(4):738-756. PubMed ID: 30537101
    [Abstract] [Full Text] [Related]

  • 6. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, Cheng H.
    Oncogene; 2018 Jan 18; 37(3):341-351. PubMed ID: 28945226
    [Abstract] [Full Text] [Related]

  • 7. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR.
    Gynecol Oncol; 2014 May 18; 133(2):346-52. PubMed ID: 24561032
    [Abstract] [Full Text] [Related]

  • 8. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R, van der Heijden MS.
    Eur Urol; 2017 Jun 18; 71(6):858-862. PubMed ID: 28108151
    [Abstract] [Full Text] [Related]

  • 9. Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
    Taurin S, Yang CH, Reyes M, Cho S, Coombs DM, Jarboe EA, Werner TL, Peterson CM, Janát-Amsbury MM.
    Int J Gynecol Cancer; 2018 Jan 18; 28(1):152-160. PubMed ID: 28953502
    [Abstract] [Full Text] [Related]

  • 10. Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
    Kraus D, Palasuberniam P, Chen B.
    Mol Cancer Ther; 2017 Nov 18; 16(11):2422-2431. PubMed ID: 28835385
    [Abstract] [Full Text] [Related]

  • 11. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.
    Clin Cancer Res; 2013 Jul 01; 19(13):3533-44. PubMed ID: 23674493
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
    Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, Chen HZ, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Ciombor KK, Hays J, Freud AG, Roychowdhury S.
    Mol Cancer Ther; 2020 Mar 01; 19(3):847-857. PubMed ID: 31911531
    [Abstract] [Full Text] [Related]

  • 13. Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
    Schoumacher M, Hurov KE, Lehár J, Yan-Neale Y, Mishina Y, Sonkin D, Korn JM, Flemming D, Jones MD, Antonakos B, Cooke VG, Steiger J, Ledell J, Stump MD, Sellers WR, Danial NN, Shao W.
    Cancer Res; 2014 Jun 15; 74(12):3294-305. PubMed ID: 24747911
    [Abstract] [Full Text] [Related]

  • 14. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA, Loch DC, Pollock PM.
    Int J Gynecol Cancer; 2012 Nov 15; 22(9):1517-26. PubMed ID: 23060048
    [Abstract] [Full Text] [Related]

  • 15. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y, Cho H, Hur W, Sim T.
    Mol Cancer Ther; 2015 Oct 15; 14(10):2292-302. PubMed ID: 26294741
    [Abstract] [Full Text] [Related]

  • 16. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.
    J Clin Oncol; 2018 Jan 20; 36(3):276-282. PubMed ID: 29182496
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr Fritcher EG, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR.
    Cancer Lett; 2016 Sep 28; 380(1):163-73. PubMed ID: 27216979
    [Abstract] [Full Text] [Related]

  • 18. In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance.
    Anisuzzaman AS, Haque A, Wang D, Rahman MA, Zhang C, Chen Z, Chen ZG, Shin DM, Amin AR.
    Mol Cancer Ther; 2017 Apr 28; 16(4):729-738. PubMed ID: 28119490
    [Abstract] [Full Text] [Related]

  • 19. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
    Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.
    Cancer Discov; 2019 Aug 28; 9(8):1064-1079. PubMed ID: 31109923
    [Abstract] [Full Text] [Related]

  • 20. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
    Boichuk S, Galembikova A, Dunaev P, Micheeva E, Valeeva E, Novikova M, Khromova N, Kopnin P.
    Molecules; 2018 Oct 15; 23(10):. PubMed ID: 30326595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.